Cell Therapy Enforcement Discretion Ending, But US FDA Still Faces Challenge Going After Bad Actors

Planned 31 May revocation of enforcement discretion for certain cell therapy products without IND or BLA is important, but experts say the FDA’s next moves are what will really shape the field and patient safety moving forward.